Fig. 2.

Haematopoiesis-specific deletion of PADI4 has no impact on BM reconstitution potential following serial transplantations. (A) Experimental design for BM transplantation experiments. 200 CD45.2⁺ BM HSCs from C57BL/6 Padi4^CTL or Padi4^CKO mice were transplanted into primary recipient mice and monitored for 16 weeks. Following this, a cohort of mice were sacrificed for analysis at 16 weeks post-transplantation and bone marrow was transplanted to secondary recipients. (B) Percentage of donor-derived CD45.2₊ cells in total BM, LSK, LK, HSC, MPP, HPC-1, HPC-2 and differentiated cell populations (granulocytes, monocytes, erythroid and B cells). Padi4^CTL, n=14; Padi4^CKO, n=13. (C) Contribution of donor-derived CD45.2⁺ cell population to total spleen WBC count and differentiated cell populations of primary recipients. Padi4^CTL, n=6; Padi4^CKO, n=6. (D,E) Secondary recipient mice were transplanted with 3000 sorted CD45.2⁺ BM LSK cells from primary recipients euthanised at 16 weeks. (D) Percentage of donor-derived CD45.2⁺ cells in total BM, LSK, LK, HSC, MPP, HPC-1, HPC-1 and differentiated cell lineages (granulocytes, monocytes, erythroid and B cells). Padi4^CTL, n=19; Padi4^CKO, n=19. Two to four donors were used per genotype. (E) Contribution of donor-derived CD45.2⁺ cell population to spleen WBC and differentiated cells of secondary recipients. Padi4^CTL, n=19; Padi4^CKO, n=19. All data are mean±s.e.m. *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001 (Mann–Whitney U-test).